Detalles de la búsqueda
1.
A randomized phase II trial of ridaforolimus, dalotuzumab, and exemestane compared with ridaforolimus and exemestane in patients with advanced breast cancer.
Breast Cancer Res Treat
; 165(3): 601-609, 2017 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-28681171
2.
Polymorphisms in cyclooxygenase-2 and epidermal growth factor receptor are associated with progression-free survival independent of K-ras in metastatic colorectal cancer patients treated with single-agent cetuximab.
Clin Cancer Res
; 14(23): 7884-95, 2008 Dec 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-19047118
3.
Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey results.
Oncology
; 72(3-4): 152-9, 2007.
Artículo
en Inglés
| MEDLINE | ID: mdl-18160805
4.
The BATTLE-2 Study: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer.
J Clin Oncol
; 34(30): 3638-3647, 2016 Oct 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-27480147
5.
A Randomized Phase II/III Study of Dalotuzumab in Combination With Cetuximab and Irinotecan in Chemorefractory, KRAS Wild-Type, Metastatic Colorectal Cancer.
J Natl Cancer Inst
; 107(12): djv258, 2015 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-26405092
6.
Retrospective US database analysis of drug utilization patterns, health care resource use, and costs associated with adjuvant interferon alfa-2b therapy for treatment of malignant melanoma following surgery.
Clinicoecon Outcomes Res
; 4: 169-76, 2012.
Artículo
en Inglés
| MEDLINE | ID: mdl-22754281
7.
Germline polymorphisms in genes involved in the IGF1 pathway predict efficacy of cetuximab in wild-type KRAS mCRC patients.
Clin Cancer Res
; 16(22): 5591-602, 2010 Nov 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-20935157
8.
Tumor necrosis factor-alpha and interleukin-1 antagonists alleviate inflammatory skin changes associated with epidermal growth factor receptor antibody therapy in mice.
Cancer Res
; 69(14): 5643-7, 2009 Jul 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-19584274
9.
Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab.
J Clin Oncol
; 25(22): 3230-7, 2007 Aug 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-17664471
10.
Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines.
J Clin Oncol
; 24(30): 4914-21, 2006 Oct 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-17050875
Resultados
1 -
10
de 10
1
Próxima >
>>